Evidence map›Paper›PMID 33607457›Full record

ArticleEuropean journal of medicinal chemistry2021

Synthesis and evaluation of cyclopentane-based muraymycin analogs targeting MraY.

Seung-Hwa Kwak, Won Young Lim, Aili Hao, Ellene H Mashalidis, Do-Yeon Kwon, Pyeonghwa Jeong, Mi Jung Kim, Seok-Yong Lee, Jiyong Hong

Open access · greenAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. New MraYAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Seung-Hwa KwakDepartment of Chemistry, Duke University, Durham, NC, 27708, United States.
Won Young LimDepartment of Chemistry, Duke University, Durham, NC, 27708, United States.
Aili HaoDepartment of Biochemistry, Duke University Medical Center, Durham, NC, 27710, United States.
Ellene H MashalidisDepartment of Biochemistry, Duke University Medical Center, Durham, NC, 27710, United States.
Do-Yeon KwonDepartment of Chemistry, Duke University, Durham, NC, 27708, United States.
Pyeonghwa JeongDepartment of Chemistry, Duke University, Durham, NC, 27708, United States.
Mi Jung KimDepartment of Chemistry, Duke University, Durham, NC, 27708, United States.
Seok-Yong LeeDepartment of Biochemistry, Duke University Medical Center, Durham, NC, 27710, United States. Electronic address: seok-yong.lee@duke.edu.
Jiyong HongDepartment of Chemistry, Duke University, Durham, NC, 27708, United States. Electronic address: jiyong.hong@duke.edu.
Duke University · USDuke Medical Center · US

Funding

Structural and Mechanistic Characterization of MraY Catalysis and InhibitionR01GM120594 · NIGMS · DUKE UNIVERSITY · PI LEE, SEOK-YONG · 2017 to 2020
$1.4M
NIGMS NIH HHS R01 GM120594
6 · The paper itself

Abstract

Antibiotic resistance is one of the most challenging global health issues and presents an urgent need for the development of new antibiotics. In this regard, phospho-MurNAc-pentapeptide translocase (MraY), an essential enzyme in the early stages of peptidoglycan biosynthesis, has emerged as a promising new antibiotic target. We recently reported the crystal structures of MraY in complex with representative members of naturally occurring nucleoside antibiotics, including muraymycin D2. However, these nucleoside antibiotics are synthetically challenging targets, which limits the scope of medicinal chemistry efforts on this class of compounds. To gain access to active muraymycin analogs with reduced structural complexity and improved synthetic tractability, we prepared and evaluated cyclopentane-based muraymycin analogs for targeting MraY. For the installation of the 1,2-syn-amino alcohol group of analogs, the diastereoselective isocyanoacetate aldol reaction was explored. The structure-activity relationship analysis of the synthesized analogs suggested that a lipophilic side chain is essential for MraY inhibition. Importantly, the analog 20 (JH-MR-23) showed antibacterial efficacy against Staphylococcus aureus. These findings provide insights into designing new muraymycin-based MraY inhibitors with improved chemical tractability.

Indexed as

Anti-Bacterial AgentsArginineBacterial ProteinsCyclopentanesEnzyme AssaysMicrobial Sensitivity TestsMolecular StructureStaphylococcus aureusStructure-Activity RelationshipTransferasesTransferases (Other Substituted Phosphate Groups)UridineAnti-Bacterial AgentsArginineBacterial ProteinsCyclopentanesmraY protein, BacteriaTransferasesTransferases (Other Substituted Phosphate Groups)UridineAntibioticsCyclopentaneMraYMuraymycinPeptidoglycan

Identifiers

PMID33607457
PMCPMC8009818
OpenAlexW3129178060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.